Cargando…
The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis
The pleiotropic benefits of statins may result from their impact on vascular inflammation. The molecular process underlying this phenomenon is not fully elucidated. Here, RNA sequencing designed to investigate gene expression patterns following CD47-SIRPα inhibition identifies a link between statins...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390974/ https://www.ncbi.nlm.nih.gov/pubmed/35990913 http://dx.doi.org/10.1038/s44161-022-00023-x |
_version_ | 1784770766581006336 |
---|---|
author | Jarr, Kai-Uwe Ye, Jianqin Kojima, Yoko Ye, Zhongde Gao, Hua Schmid, Sofie Luo, Lingfeng Baylis, Richard A. Lotfi, Mozhgan Lopez, Nicolas Eberhard, Anne V. Smith, Bryan Ronain Weissman, Irving L. Maegdefessel, Lars Leeper, Nicholas J. |
author_facet | Jarr, Kai-Uwe Ye, Jianqin Kojima, Yoko Ye, Zhongde Gao, Hua Schmid, Sofie Luo, Lingfeng Baylis, Richard A. Lotfi, Mozhgan Lopez, Nicolas Eberhard, Anne V. Smith, Bryan Ronain Weissman, Irving L. Maegdefessel, Lars Leeper, Nicholas J. |
author_sort | Jarr, Kai-Uwe |
collection | PubMed |
description | The pleiotropic benefits of statins may result from their impact on vascular inflammation. The molecular process underlying this phenomenon is not fully elucidated. Here, RNA sequencing designed to investigate gene expression patterns following CD47-SIRPα inhibition identifies a link between statins, efferocytosis, and vascular inflammation. In vivo and in vitro studies provide evidence that statins augment programmed cell removal by inhibiting the nuclear translocation of NFκB1 p50 and suppressing the expression of the critical ‘don’t eat me’ molecule, CD47. Statins amplify the phagocytic capacity of macrophages, and thus the anti-atherosclerotic effects of CD47-SIRPα blockade, in an additive manner. Analyses of clinical biobank specimens suggest a similar link between statins and CD47 expression in humans, highlighting the potential translational implications. Taken together, our findings identify efferocytosis and CD47 as pivotal mediators of statin pleiotropy. In turn, statins amplify the anti-atherosclerotic effects of pro-phagocytic therapies independently of any lipid-lowering effect. |
format | Online Article Text |
id | pubmed-9390974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-93909742022-09-07 The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis Jarr, Kai-Uwe Ye, Jianqin Kojima, Yoko Ye, Zhongde Gao, Hua Schmid, Sofie Luo, Lingfeng Baylis, Richard A. Lotfi, Mozhgan Lopez, Nicolas Eberhard, Anne V. Smith, Bryan Ronain Weissman, Irving L. Maegdefessel, Lars Leeper, Nicholas J. Nat Cardiovasc Res Article The pleiotropic benefits of statins may result from their impact on vascular inflammation. The molecular process underlying this phenomenon is not fully elucidated. Here, RNA sequencing designed to investigate gene expression patterns following CD47-SIRPα inhibition identifies a link between statins, efferocytosis, and vascular inflammation. In vivo and in vitro studies provide evidence that statins augment programmed cell removal by inhibiting the nuclear translocation of NFκB1 p50 and suppressing the expression of the critical ‘don’t eat me’ molecule, CD47. Statins amplify the phagocytic capacity of macrophages, and thus the anti-atherosclerotic effects of CD47-SIRPα blockade, in an additive manner. Analyses of clinical biobank specimens suggest a similar link between statins and CD47 expression in humans, highlighting the potential translational implications. Taken together, our findings identify efferocytosis and CD47 as pivotal mediators of statin pleiotropy. In turn, statins amplify the anti-atherosclerotic effects of pro-phagocytic therapies independently of any lipid-lowering effect. 2022-03 2022-03-07 /pmc/articles/PMC9390974/ /pubmed/35990913 http://dx.doi.org/10.1038/s44161-022-00023-x Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms |
spellingShingle | Article Jarr, Kai-Uwe Ye, Jianqin Kojima, Yoko Ye, Zhongde Gao, Hua Schmid, Sofie Luo, Lingfeng Baylis, Richard A. Lotfi, Mozhgan Lopez, Nicolas Eberhard, Anne V. Smith, Bryan Ronain Weissman, Irving L. Maegdefessel, Lars Leeper, Nicholas J. The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis |
title | The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis |
title_full | The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis |
title_fullStr | The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis |
title_full_unstemmed | The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis |
title_short | The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis |
title_sort | pleiotropic benefits of statins include the ability to reduce cd47 and amplify the effect of pro-efferocytic therapies in atherosclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390974/ https://www.ncbi.nlm.nih.gov/pubmed/35990913 http://dx.doi.org/10.1038/s44161-022-00023-x |
work_keys_str_mv | AT jarrkaiuwe thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT yejianqin thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT kojimayoko thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT yezhongde thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT gaohua thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT schmidsofie thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT luolingfeng thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT baylisricharda thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT lotfimozhgan thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT lopeznicolas thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT eberhardannev thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT smithbryanronain thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT weissmanirvingl thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT maegdefessellars thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT leepernicholasj thepleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT jarrkaiuwe pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT yejianqin pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT kojimayoko pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT yezhongde pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT gaohua pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT schmidsofie pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT luolingfeng pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT baylisricharda pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT lotfimozhgan pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT lopeznicolas pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT eberhardannev pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT smithbryanronain pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT weissmanirvingl pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT maegdefessellars pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis AT leepernicholasj pleiotropicbenefitsofstatinsincludetheabilitytoreducecd47andamplifytheeffectofproefferocytictherapiesinatherosclerosis |